Slider

THE SYMPATH SYMPOSIUM ON TARGETING SYNUCLEINOPATHIES WILL BRING TOGETHER WORLD-LEADING EXPERTS FROM EUROPE AND THE US TO DISCUSS RECENT PROGRESS IN DEVELOPING THERAPEUTIC VACCINATIONS TARGETING PARKINSON’S DISEASE (PD) AND MULTIPLE SYSTEM ATROPHY (MSA). THE PROGRAMME INCLUDES PATHOGENESIS, BIOMARKERS AND CLINICAL CHALLENGES IN PD AND MSA.

 

ORGANISING COMMITTEE


GERGANA GALABOVA

AFFIRIS AG
Austria

Gergana Galabova completed her veterinary medical studies in 2000 in Bulgaria before moving to Austria for her doctoral and post-doctoral training. In 2009, Gergana left academia to join the biotech company AFFiRiS AG where she is now head of the Neurodegeneration Department. Her team focus on the preclinical research and development of immunotherapy for the treatment of Parkinson’s disease and Alzheimer’s disease.
Photo: © AFFiRiS / Petra Spiola

WASSILIOS MEISSNER

University Hospital Bordeaux
France

Wassilios Meissner is Professor of Neurology at the University Bordeaux 2 and the University Hospital Bordeaux. He has since 2012 served as co-chair of the French National Reference Centre for multiple-system atrophy. His current research interests focus on multiple-system atrophy pathophysiology (preclinical and clinical), biological and clinical markers of disease progression and treatment.
Photo: © Markus Schieder – CREVO Creative Volume e.U.

GÜNTHER STAFFLER

AFFIRIS AG
Austria

Günther Staffler completed his degree in biochemistry and immunology at the University of Vienna, where he subsequently lectured. After a postdoctoral period he moved into the biotech sector where he was responsible for the establishment of the microbiology programme and preclinical development. Günther joined AFFiRiS to lead the immunology department; he is now Chief Technology Officer (CTO) and member of AFFiRiS’s Executive Board.
Photo: © AFFiRiS / Petra Spiola


LOCATION


We are proud that the SYMPATH symposium takes place at the new, state-of-the-art Institute of Molecular Pathology (IMP) research building completed in October 2016. We wish to extend our thanks to the IMP for granting us the opportunity to use their exceptional facilities for this event.

The Vienna BioCenter (VBC) is located in the innovative St. Marx district. With 90,000 m2 of modern offices and lab facilities for life sciences research, the VBC hosts academic and industrial research institutes, in addition to being a hot spot for enterprises in the field of life sciences and science communication. It is a unique location, with the VBC harmonising perfectly with this recently revitalised area of the city, formerly Vienna’s main cattle market.

Visiting a conference provides not only the opportunity to meet other scientists but also to soak up the spirit of the host city and its surroundings. Vienna has transformed from a Roman settlement to the capital of the Austro-Hungarian Empire before finally becoming the capital of the modern Austrian state with over 1.75 million inhabitants. For several years Vienna has been ranked the most liveable city in the world in regard to the quality of life, reflecting not only political, social and economic factors but also health, education and public services, including transportation. When visiting Vienna you will experience the city’s special mix of historical heritage and modernity not only when visiting museums, concerts and the various theatres but also when relaxing at one of the numerous restaurants, bars or classical “Heurigen” in the vineyards of Vienna.

MORE LOCATION DETAILS

© IMP / Kuball

© IMP / Kuball

imp-logo_s

neumarxlogoorange

 

THE SYMPATH PROJECT


SYMPATH is an EU funded research project to assess the safety of the first two therapeutic vaccine candidates for Parkinson´s disease and multiple-system atrophy that could hinder disease progression. The aim is to develop a symptomatic effective and potentially disease modifying  vaccine.

VISIT PROJECT WEBSITE